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Abstract 
Tau is a microtubule-binding protein that is important for the stability of neuronal axons. It is 
normally expressed within neurons and is also secreted into the brain interstitial fluid that 
communicates freely with cerebrospinal fluid (CSF) and, in a more restricted manner, blood 
via the glymphatic clearance system of the brain. In Alzheimer’s disease (AD), neuroaxonal 
degeneration results in increased release of tau from neurons. Further, tau is truncated and 
phosphorylated, which leads to aggregation of tau in neurofibrillary tangles of the proximal 
axoplasm. Neuroaxonal degeneration and tangle formation are reflected by increased 
concentrations of total tau (T-tau, measured using assays that detect most forms of tau) and 
phospho-tau (P-tau, measured using assays with antibodies specific to phosphorylated forms 
of tau). In AD CSF, both T-tau and P-tau concentrations are increased. In stroke and other 
CNS disorders with neuroaxonal injury but without tangles, T-tau is selectively increased, 
whilst P-tau concentration often stays normal. In tauopathies (diseases with both 
neurodegeneration and neurofibrillary tangles) other than AD, CSF T-tau and P-tau 
concentrations are typically unaltered, which is a puzzling result that warrants further 
investigation. In the current review, I discuss the association of T-tau and P-tau concentrations 
in body fluids with neuropathological changes, imaging findings and clinical features in AD 
and other CNS diseases. 
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Background 
In 1986, one year after the sequencing of amyloid β (A) in senile plaques in Alzheimer’s 
disease (AD) brains [1], data were published showing that neurofibrillary tangles (the other 
major neuropathological hallmark of AD) are composed of abnormally phosphorylated and 
truncated forms of tau [2, 3]. Tau is a microtubule-binding axonal protein that promotes 
microtubule assembly and stability [4]. Abnormal phosphorylation and truncation of tau may 
lead to disassembly of microtubules and impaired axonal transport with compromised 
neuronal function and tau aggregation into paired helical filaments and neurofibrillary tangles 
[5]. Apart from executing important intracellular functions, tau is normally secreted from 
neurons into the brain interstitial fluid [6, 7]. This fluid communicates freely with 
cerebrospinal fluid (CSF) and, in a more restricted manner that is regulated by the glymphatic 
clearance system of the brain, with blood, where tau may be enzymatically degraded and 
cleared from the body by unknown mechanisms. Several methods to measure total tau (T-tau) 
and phospho-tau (P-tau) in CSF have been developed. They are reviewed in detail below and 
their utility in differential diagnostics of neurodegenerative diseases is summarized in Table 1.  
 
CSF T-tau 
The first CSF T-tau assay was published in 1993 [8]. This assay was a sandwich ELISA in 
which a monoclonal antibody against the mid-domain of tau was combined with a polyclonal 
anti-tau antiserum. Two years later, the first assay based on three mid-region monoclonal 
antibodies that recognise all tau isoforms irrespective of phosphorylation state was published 
[9]. AD patients displayed clearly increased T-tau concentrations in their CSF [8, 9], a finding 
that has been replicated in hundreds of papers, using different assays, in many different 
clinical contexts [10]. In response to acute brain injury, CSF T-tau concentrations are 
dynamic; they increase during the first few days following the injury and stay elevated for 
some weeks until they normalise [11, 12]. This has led to the view that increased CSF T-tau 
concentration reflects ongoing axonal injury or degeneration, which in turn may indicate 
disease intensity. In AD-type neurodegeneration, CSF T-tau concentrations are stably 
increased over many years [13].  
 
CSF P-tau 
The first CSF assay for P-tau, the form of tau that is thought to represent neurofibrillary 
tangles, was published in 1995 [9]. Since then, P-tau assays for different forms of 
phosphorylated tau protein have been examined [14]. They correlate well and associate with 
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AD in a similar manner [14]. There are at present only 3 conditions in addition to AD in 
which elevated CSF P-tau levels have been reported, none of which is an important 
differential diagnosis of AD: (i) in term and pre-term newborns, possibly reflecting 
physiological tau phosphorylation in brain development [15], (ii) in herpes encephalitis [16], 
and (iii) in superficial CNS siderosis [17, 18].  
 
CSF tau – relation to pathology 
In AD and normal pressure hydrocephalus, CSF P-tau concentration correlates with 
neurofibrillary tangle pathology [19, 20]. The major outstanding research question regarding 
P-tau is why other tauopathies, like frontotemporal dementias and progressive supranuclear 
palsy, do not show increased CSF P-tau concentration, at least not as systematically as AD 
does. It is possible that these disorders show disease-specific tau phosphorylation, or that tau 
is processed or truncated in a way that is not recognised by currently available assays, which 
is an area in need of further research.  
 
CSF tau – relation to imaging 
One limitation with CSF T-tau and P-tau is that lumbar CSF concentrations will never give 
information on the anatomic location of the pathology. Nevertheless, it has been shown that 
CSF T-tau concentration correlates with structural imaging measures of hippocampal atrophy 
[21] and grey matter degeneration [22], which is logical given the high expression of tau in 
thin unmyelinated axons of the cortex [23]. Additionally, rapid progress is being made on new 
positron emission tomography (PET) tracers for studying tau pathology in living humans. The 
results so far show that CSF and PET tau markers correlate [4]. In classical AD, the two may 
be more or less interchangeable, but in atypical forms of AD, tau PET may be superior. This 
was recently illustrated in a case report that described a young patient with progressive short 
term memory impairment and florid sensory symptoms [24]. CSF A42 was abnormal and 
18F-flutemetamol PET showed a distribution of amyloid-β fibrils similar to sporadic AD. 
CSF T-tau and P-tau concentrations were normal, but the pattern of tau pathology, revealed 
using 18F-AV1451 PET, showed higher uptake in posterior cingulate, precuneus, parietal and 
occipital cortices, as compared to late-onset sporadic AD. Further, tau pathology exhibited a 
very clear inverse relationship with 18F-fluorodeoxyglucose metabolism, indicating neuronal 
hypometabolism in regions affected by tau aggregates. Genetic testing revealed a mutation of 
the presenilin-1 gene (Thr116Asn), previously described in a Danish family with familial AD 
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[25]. Tau PET is currently being examined in regards to its usefulness to detect tauopathies 
other than AD, where CSF tau markers currently fail. 
 
In clinical trials of disease-modifying drug candidates against AD, CSF and PET tau markers 
may provide complementary information. Tau PET may be used to detect changes over 
months to years in tau pathology, whilst CSF T-tau and P-tau may be used to monitor changes 
in the neuronal release pattern of these molecules over weeks to months. This reasoning is 
presently hypothetical and waits formal testing in clinical trials.  
 
CSF tau – relation to clinical features 
CSF T-tau and P-tau are markers of disease intensity in AD; the higher concentrations, the 
more rapid clinical disease progression [26, 27]. The most extreme neurodegenerative 
condition we are aware of, Creutzfeldt-Jakob disease, is associated with very pronounced CSF 
T-tau elevations that are often orders of magnitude higher than what is typically seen in AD 
[28]. 
 
Plasma tau 
Standard ELISAs for T-tau were recently transferred onto the Single molecule array (Simoa) 
platform, which allows for the ultrasensitive measurement of tau in blood [29]. There is so far 
no assay for P-tau in plasma. Plasma T-tau concentrations correlate poorly with CSF [30], but 
in acute hypoxic brain injury, a biphasic release of tau into the bloodstream was observed 
with a first peak occurring during the first few hours post-injury and a second broad peak 
occurring after a few more days; these increases were predictive of outcome [29]. In the 
dementia stage of AD, plasma tau concentrations are slightly increased compared with 
cognitively normal control individuals, but not as clearly as in CSF [30], which is a well-
replicated finding [10]. In a study on concussed professional ice hockey players, plasma T-tau 
concentration at 1 hour post-injury was increased compared with preseason concentrations 
and predicted return-to-play time with high accuracy [31]. In another study of 34 patients with 
varying degree of traumatic brain injury (TBI), plasma tau concentrations in samples collected 
within 24 hours post-injury showed high accuracy to differentiate complicated mild TBI from 
controls (area under the curve 0.901) [32]. Recently, Olivera et al. reported increased mean 
plasma tau concentration in military personnel with a history of self-reported TBI compared 
with controls without such a history [33]. Additionally, post-concussive symptoms correlated 
with plasma tau concentration in the TBI group, suggesting that the increase, although 
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variable, might be of pathophysiological relevance [33]. The expression of tau is brain-
enriched, but tau is also detectable at both mRNA and protein level in salivary glands and 
kidney (http://www.proteinatlas.org/ENSG00000186868-MAPT/tissue). This is an important 
potential confounder that may help explain the poor correlation of plasma with CSF tau. The 
half-life of tau also appears to be much shorter (hours) in plasma [29] than in CSF (weeks) 
[11].  
 
Novel fluid biomarkers for tau 
Tau proteins constitute a family of six isoforms ranging from 352-441 amino acids in size. 
The longest isoform in the CNS has four repeats (R1, R2, R3 and R4) and two inserts (441 
amino acids in total), whereas the shortest isoform has three repeats (R1, R3 and R4) and no 
insert (352 amino acids in total) [34]. All of the six tau isoforms are present in an often 
hyperphosphorylated state in paired helical filaments from AD. In addition, there are 
endogenous fragments of tau; these fragments often lack different parts of the C-terminus [35]. 
A few years ago, ultrasensitive assays specific for 4R-tau and 3R-tau were developed [36]. 
Selective decreases of 4R-tau in CSF of progressive nuclear palsy and AD patients compared 
with controls, and lower 4R-tau levels in AD compared with Parkinson’s disease dementia 
were reported, which was a promising result, but the assay has been difficult to standardize 
and the results are in need of replication. Recently, Lewczuk and colleagues reported 
increased CSF concentration of non-phosphorylated tau using a novel tau assay that 
specifically measures tau not phosphorylated at amino acids 175, 181 or 231 [37]. Using a 
new mass spectrometry workflow to enhance the detection of phosphoproteome components 
of AD brain tissue in CSF and enable the quantification of these analytes, over 75% coverage 
of full-length (2N4R) tau was detected in the CSF with 47 phosphopeptides covering 31 
different phosphorylation sites. In a pilot study of a few AD and control CSF samples, 11 tau 
phosphopeptides were up-regulated by at least 40%, along with an overall increase in tau 
levels in the CSF of AD patients relative to controls; a few phosphopeptides were down-
regulated [38]. Using another mass spectrometry approach, tau peptides along the entire 
molecule were detected in CSF and the peptide abundance pattern was similar in progressive 
supranuclear palsy and dementia with Lewy bodies but distinct in AD [39_ENREF_39]. 
These data emphasise the complexity of tau as a biomarker and warrant further investigation.  
 
Standardization of fluid biomarker assays for tau 
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There is as yet no certified reference method or material for the most established AD 
biomarkers T-tau and P-tau, but such work is currently ongoing in the International 
Federation of Clinical Chemistry and Laboratory Medicine working group on CSF proteins. A 
candidate reference method for CSF T-tau has been published [40].  
 
Conclusions 
CSF T-tau and P-tau are markers of AD-type neurodegeneration and tangle formation. Other 
tauopathies show mostly normal CSF tau protein concentrations, potentially due to release of 
other tau forms that the current assays fail to detect. One hypothesis regarding the reason for 
the AD-specific increase in CSF T-tau and P-tau concentrations is that neuronal CSF tau 
protein secretion may be induced by alzheimerogenic factors such as A42. Tau is a 
complicated biomolecule with several isoforms and fragments. More tau markers are to be 
expected in the near future in the light of new mass spectrometric findings. CSF and PET tau 
markers seem to provide complementary information on AD pathology and should as much as 
possible be analysed in parallel on patients in different stages of the disease, as well as in 
atypical forms of AD and in other tauopathies, to increase our knowledge on how to best 
interpret the two measures. 
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Table 1. CSF total- and phospho-tau concentrations in neurodegenerative diseases and 
common differential diagnoses 
Disease Total-tau concentration Phospho-tau concentration 
Alzheimer’s disease Medium to strong increase Medium to strong increase 
Vascular dementia Normal to strong increase Normal 
Frontotemporal dementia Normal to slight increase Normal 
Dementia with Lewy bodies Normal to slight increase Normal 
Parkinson’s disease Normal Normal 
Atypical parkinsonian 
disorders 
Normal to slight increase Normal 
Creutzfeldt-Jakob’s disease Very strong increase Normal 
Stable mild cognitive 
impairment 
Normal Normal 
Normal aging Normal Normal 
Depression Normal  Normal 
 
